Literature DB >> 21509165

Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management.

Kang Min Lee1, Hee Woo Lee, Seung Yeon Kim, Hyeon Jeong Lee, Dong Hwan Kim, Joongbum Cho, Dong Ho Kim, Jung Sub Lim, Jin Kyung Lee, Jun Ah Lee.   

Abstract

High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G(2) is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Entities:  

Keywords:  Child; Complication; Management; Methotrexate; Osteosarcoma

Year:  2011        PMID： 21509165      PMCID： PMC3072537          DOI： 10.4143/crt.2011.43.1.67

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN： 1598-2998            Impact factor:   4.679


  15 in total

Review 1.  Understanding and managing methotrexate nephrotoxicity.

Authors:  Brigitte C Widemann; Peter C Adamson
Journal:  Oncologist       Date:  2006-06

2.  Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis.

Authors:  I Djerassi; W Ciesielka; J S Kim
Journal:  Cancer Treat Rep       Date:  1977-07

3.  Serious methotrexate toxicity caused by interaction with ibuprofen.

Authors:  W F Cassano
Journal:  Am J Pediatr Hematol Oncol       Date:  1989

4.  Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.

Authors:  B C Widemann; M L Hetherington; R F Murphy; F M Balis; P C Adamson
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

5.  Effective removal of methotrexate by high-flux hemodialysis.

Authors:  Jeffrey M Saland; Patrick J Leavey; Robert O Bash; Eleonora Hansch; Gerald S Arbus; Raymond Quigley
Journal:  Pediatr Nephrol       Date:  2002-08-09       Impact factor: 3.714

6.  Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.

Authors:  Bijesh Kumar Biswal; Rama Shanker Verma
Journal:  J Biochem       Date:  2009-08-19       Impact factor: 3.387

7.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.

Authors:  P A Meyers; G Heller; J Healey; A Huvos; J Lane; R Marcove; A Applewhite; V Vlamis; G Rosen
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

8.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

Authors:  M V Relling; D Fairclough; D Ayers; W R Crom; J H Rodman; C H Pui; W E Evans
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

9.  Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.

Authors:  H T Abelson; M T Fosburg; G P Beardsley; A M Goorin; C Gorka; M Link; D Link
Journal:  J Clin Oncol       Date:  1983-03       Impact factor: 44.544

10.  Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.

Authors:  N Delepine; G Delepine; H Cornille; F Brion; P Arnaud; J C Desbois
Journal:  Anticancer Res       Date:  1995 Mar-Apr       Impact factor: 2.480
View more
  2 in total

1.  Assessing the percent of necrosis after neoadjuvant chemotherapy with 24hr infusional cisplatin/3 days Doxorubicin intermittent with Ifosfamide-Doxorubicin for osteosarcoma.

Authors:  Mozhgan Aalam Samimi; Nooshin Mirkheshti; Abdolreza Pazouki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

2.  Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.

Authors:  Wei Zhang; Qing Zhang; Ting-Ting Zheng; Jian-Cun Zhen; Xiao-Hui Niu
Journal:  Chin Med J (Engl)       Date:  2016-11-05       Impact factor: 2.628
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.